LC Laurie Gaspar, Hak Choy There are new data on the combination of targeted agents and radiotherapy. There have been studies or in the paths, the combination of radiation with EGFR inhibitors, antiangiogenic agent and multi-target, such as pemetrexed and ZD6474. The interest in EGFR buy PF-01367338 inhibitors in combination with radiotherapy has been following the positive results of a randomized phase III study of cetuximab and radiation versus radiation alone in head and neck to. Patients were randomized to body cetuximab, a monoclonal antibody Obtained with the EGFR, have again U is a loading dose at week 1, then w Chentliche dose radiation. There were no chemotherapy in this study.
The median survival time was 54 months for patients U cetuximab and 28 months in the control arm On. RTOG 0324 was a phase II study of cetuximab and chemoradiotherapy in patients with stage III NSCLC. One week after a dose of cetuximab, the patient again Simultaneous irradiation with U w Weekly cetuximab, paclitaxel, ON-01910 and carboplatin. After completion of concurrent chemoradiation, patients were again U w 6 weeks Weekly cetuximab with 2 cycles of CP in ligand distances Of 3 times per week given. The study was closed in May 2005 after the execution of 93 patients. The treatment was tolerated einigerma s: 9% of patients with grade 4 or 5 toxicity t, and 3 patients developed grade 4 or 5 pneumonia. Preferences INDICATIVE data survive Einhorn et al. J Thorac Oncol page 15 Author manuscript, increases available in PMC 13th June 2012.
show that the survival rate after 1 year 68%. RTOG is currently planning a phase III trial compared cetuximab with chemoradiotherapy alone and concurrent chemoradiotherapy. Other studies have focused on the inhibition of EGFR as a maintenance therapy after standard chemo-radiotherapy in locally advanced NSCLC. SWOG 0023 was a randomized Phase III trial for patients with unresectable stage III NSCLC. After recording, all patients were again U radiochemotherapy and 3 cycles of docetaxel consolidation. The patients were then randomized to maintenance therapy with gefitinib or placebo. Patients were measured by stage IIIA IIIB disadvantages, no measurable disease, compared, and squamous from non-squamous histology.
This study was stopped early because an interim analysis revealed that the gefitinib arm could not be closed for a median survival time of more than the placebo group. The median survival time was 19 months for all patients enrolled in the study. There was no statistically significant difference in the H FREQUENCY observed from pneumonia of grade 3 or h Forth between the two treatment groups. There are also big interest in it the combination anti-angiogenic agents with standard chemotherapy in radio, stage III NSCLC. Pr Clinical studies have shown increased apoptosis of tumor cells with increasing doses of anti-angiogenic agents with radiation therapy. SWOG 0533 is a Phase I trial is underway involving bevacizumab, an antiangiogenic agent in the treatment of locally advanced stage III NSCLC. All patients receiving concomitant cisplatin, etoposide and 64.8 Gy thoracic radiotherapy followed by 3 cycles of docetaxel consolidation. With each new cohort of patients who b